ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study

Zhao, Jingzhu; Chi, Yihebali; Hu, Chuanxiang; Chen, Xiaohong; Ge, Minghua; Zhang, Yuan; Guo, Zhuming; Wang, Jun; Chen, Jie; Zhang, Jiewu; Cheng, Ying; Li, Zhendong; Liu, Hui; Qin, Jianwu; Zhu, Jingqiang; Cheng, Ruochuan; Xu, Zhengang; Li, Dapeng; Tang, Pingzhang; Gao, Ming*; Zheng, Xiangqian*哈尔滨医科大学; 四川大学; 郑州大学; 中国医科大学; 中国医学科学院; 中山大学; 中国科学院研究生院; 中国医学科学院北京协和医院; 1
Frontiers in Oncology2022-11-22DOI: 10.3389/fonc.2022.852032
2被引7阅读
引用收藏
分享

摘要

BackgroundMedullary thyroid carcinoma (MTC) is a rare type of thyroid cancer; however, it accounted for 13.4% of the disease-specific mortalities. ALTER01031 (NCT02586350) was a randomised, placebo-controlled phase 2b trial that evaluated the efficacy and safety of anlotinib in locally advanced or metastatic MTC. This post hoc analysis aimed to evaluate the efficacy and safety of anlotinib in older patients and those with bone metastases using ALTER01031. MethodsIn ALTER01031, anlotinib significantly prolonged the median progression-free survival (PFS) from 11.1 months to 20.7 months compared with placebo in the whole population. Patients who were older (>= 50 years) or had bone metastases were selected. PFS and overall survival (OS) were estimated and compared between patients receiving anlotinib or placebo in each subgroup. A sub-analysis of tumour response and safety was also performed. ResultsPatients with older age or bone metastases experienced rapid disease progression as the median PFS was 6.8 months and 7.0 months respectively in the placebo group. Anlotinib significantly improved the median PFS to 17.5 months (P = 0.002) and 20.7 months (P = 0.029) with hazard ratio (HR) of 0.31 (95% CI, 0.15-0.68) and 0.44 (95% CI, 0.20-0.94) compared with placebo. Significant benefit in OS was observed in patients with older age after a longer follow-up (HR = 0.47 [95% CI, 0.22-0.99], P = 0.041). The safety profile of these subgroups was similar to that of the entire population. ConclusionThis sub-analysis demonstrated significant survival benefits and favourable safety of anlotinib in patients with MTC who had old age or bone metastases, supporting the feasibility of anlotinib in these patients.

学科与关键词

关键词
medullary thyroid carcinomaanlotinibsubgroup analysisolder agebone metastases
相关
加载中…
  • Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer Efficacy, Safety, and Survival Predictors
    Liu, Qingxing; Kulkarni, Harshad R.; Zhao, Tianzhi; Schuchardt, Christiane; Chen, Xiaoyuan; Zhu, Zhaohui*; Zhang, Jingjing*; Baum, Richard P.*CLINICAL NUCLEAR MEDICINE, 2023, 48(3): 221-227.被引 2
  • Prognosis of radiotherapy in medullary thyroid carcinoma patients without distant metastasis
    Huang, Shaojun; Zhong, Jiana; Zhang, Zhen; Chen, Rongping; Li, Jitong; Sun, Jia*; Chen, Hong*Translational Cancer Research, 2021, 10(11): 4714-+.被引 1
  • Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial
    Cheng, Ying*; Wang, Qiming; Li, Kai; Shi, Jianhua; Wu, Lin; Han, Baohui; Chen, Gongyan; He, Jianxing; Wang, Jie; Qin, Haifeng; Li, XiaolingCancer Medicine, 2022, 11(4): 1081-1087.被引 9
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-11-22
卷期
第 12 卷
页码
852032
DOI
10.3389/fonc.2022.852032
期刊等级
3区
成果收录
SCIE
资助标注
Chia Tai TianQing Pharmaceutical Group Co., Ltd.; [ALTER01031]

作者

  • Z

    Zhao, Jingzhu (第一作者)

    tianjin med univ canc inst & hosp

  • C

    Chi, Yihebali

    chinese acad med sci · peking union med coll

查看全部 21 位作者收起作者
  • H

    Hu, Chuanxiang

    tianjin med univ canc inst & hosp

  • C

    Chen, Xiaohong

    beijing inst otolaryngol · capital med univ

  • G

    Ge, Minghua

    univ chinese acad sci · zhejiang prov peoples hosp

  • Z

    Zhang, Yuan

    nanjing med univ

  • G

    Guo, Zhuming

    sun yat sen univ

  • W

    Wang, Jun

  • C

    Chen, Jie

    1 · hunan canc hosp

  • Z

    Zhang, Jiewu

    harbin med univ

  • C

    Cheng, Ying

  • L

    Li, Zhendong

    china med univ · liaoning tumor hosp

  • L

    Liu, Hui

    fujian canc hosp

  • Q

    Qin, Jianwu

    zhengzhou univ

  • Z

    Zhu, Jingqiang

    sichuan univ

  • C

    Cheng, Ruochuan

    kunming med univ

  • X

    Xu, Zhengang

    chinese acad med sci · peking union med coll

  • L

    Li, Dapeng

    tianjin med univ canc inst & hosp

  • T

    Tang, Pingzhang

    chinese acad med sci · peking union med coll

  • G

    Gao, Ming (通讯)

    tianjin med univ canc inst & hosp · tianjin union med ctr

  • Z

    Zheng, Xiangqian (通讯)

    tianjin med univ canc inst & hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417